1. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006; 48:2293–2300. PMID:
17161262.
Article
2. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008; 371:1921–1926. PMID:
18539224.
Article
3. Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab. 2013; 98:1409–1416. PMID:
23471976.
Article
4. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45:1243–1248. PMID:
15837256.
Article
5. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003; 63:1791–1800. PMID:
12675855.
Article
6. Freel EM, Mark PB, Weir RA, McQuarrie EP, Allan K, Dargie HJ, et al. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging. 2012; 5:740–747. PMID:
23019275.
7. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017; 69:1811–1820. PMID:
28385310.
8. Lim JS, Park S, Park SI, Oh YT, Choi E, Kim JY, et al. Cardiac dysfunction in association with increased inflammatory markers in primary aldosteronism. Endocrinol Metab (Seoul). 2016; 31:567–576. PMID:
27834080.
Article
9. Petramala L, Violi F, Letizia C. Aldosterone-induced oxidative stress: a potential mechanism of aldosterone autonomy in primary aldosteronism. J Hypertens. 2014; 32:2281. PMID:
25271920.
10. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993; 366:575–580. PMID:
8255296.
Article
11. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005; 111:871–878. PMID:
15710759.
Article
12. Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab. 2012; 97:E75–E79. PMID:
22013107.
Article
13. Rossi GP. Hyperparathyroidism, arterial hypertension and aortic stiffness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage? Hypertens Res. 2011; 34:286–288. PMID:
21160479.
Article
14. Gruson D, Buglioni A, Burnett JC Jr. PTH: potential role in management of heart failure. Clin Chim Acta. 2014; 433:290–296. PMID:
24704306.
Article
15. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, et al. Guidelines for the diagnosis and treatment of primary aldosteronism: the Japan Endocrine Society 2009. Endocr J. 2011; 58:711–721. PMID:
21828936.
Article
16. Park SI, Rhee Y, Lim JS, Park S, Kang SW, Lee MS, et al. Right adrenal venography findings correlated with C-arm CT for selection during C-arm CT-assisted adrenal vein sampling in primary aldosteronism. Cardiovasc Intervent Radiol. 2014; 37:1469–1475. PMID:
24352864.
Article
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18:1440–1463. PMID:
16376782.
Article
18. Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018; 6:41–50. PMID:
29129575.
Article
19. Notsu M, Yamauchi M, Yamamoto M, Nawata K, Sugimoto T. Primary aldosteronism as a risk factor for vertebral fracture. J Clin Endocrinol Metab. 2017; 102:1237–1243. PMID:
28182819.
Article
20. Wu VC, Chang CH, Wang CY, Lin YH, Kao TW, Lin PC, et al. Risk of fracture in primary aldosteronism: a population-based cohort study. J Bone Miner Res. 2017; 32:743–752. PMID:
27862274.
Article
21. Kim BJ, Kwak MK, Ahn SH, Kim H, Lee SH, Koh JM. Lower trabecular bone score in patients with primary aldosteronism: human skeletal deterioration by aldosterone excess. J Clin Endocrinol Metab. 2018; 103:615–621. PMID:
29126119.
Article
22. Reid IR, Birstow SM, Bolland MJ. Calcium and cardiovascular disease. Endocrinol Metab (Seoul). 2017; 32:339–349. PMID:
28956363.
Article
23. Reid IR, Gamble GD, Bolland MJ. Circulating calcium concentrations, vascular disease and mortality: a systematic review. J Intern Med. 2016; 279:524–540. PMID:
26749423.
Article
24. Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008; 156:556–563. PMID:
18760141.
Article
25. Yu N, Donnan PT, Flynn RW, Murphy MJ, Smith D, Rudman A, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf). 2010; 73:30–34. PMID:
20039887.
26. Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C, et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery. 2009; 146:1035–1041. PMID:
19958930.
Article
27. Barkan A, Marilus R, Winkelsberg G, Yeshurun D, Blum I. Primary hyperparathyroidism: possible cause of primary hyperaldosteronism in a 60-year-old woman. J Clin Endocrinol Metab. 1980; 51:144–147. PMID:
6991517.
Article
28. Rutledge MR, Farah V, Adeboye AA, Seawell MR, Bhattacharya SK, Weber KT. Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism. Cardiovasc Drugs Ther. 2013; 27:161–170. PMID:
22373564.
Article
29. Tomaschitz A, Pilz S. Interplay between sodium and calcium regulatory hormones: a clinically relevant research field. Hypertension. 2014; 63:212–214. PMID:
24191288.
30. Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology. 1991; 129:489–495. PMID:
1647306.
Article
31. Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab. 2001; 280:E209–E213. PMID:
11158922.
Article
32. Zia AA, Kamalov G, Newman KP, McGee JE, Bhattacharya SK, Ahokas RA, et al. From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation. Hypertens Res. 2010; 33:1091–1101. PMID:
20827279.
Article
33. Schluter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 1998; 37:34–41. PMID:
9539855.
34. Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol. 1993; 264(6 Pt 2):H1998–H2006. PMID:
8322930.
Article
35. Tomaschitz A, Pilz S, Rus-Machan J, Meinitzer A, Brandenburg VM, Scharnagl H, et al. Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. Int J Cardiol. 2015; 184:710–716. PMID:
25777071.
Article
36. Ceccoli L, Ronconi V, Giovannini L, Marcheggiani M, Turchi F, Boscaro M, et al. Bone health and aldosterone excess. Osteoporos Int. 2013; 24:2801–2807. PMID:
23695421.
Article
37. Petramala L, Zinnamosca L, Settevendemmie A, Marinelli C, Nardi M, Concistre A, et al. Bone and mineral metabolism in patients with primary aldosteronism. Int J Endocrinol. 2014; 2014:836529. PMID:
24864141.
Article
38. Tyler Miller R. Control of renal calcium, phosphate, electrolyte, and water excretion by the calcium-sensing receptor. Best Pract Res Clin Endocrinol Metab. 2013; 27:345–358. PMID:
23856264.
Article
39. Friedman PA. Codependence of renal calcium and sodium transport. Annu Rev Physiol. 1998; 60:179–197. PMID:
9558460.
Article